Li WC, Wang Z, Gao J, et al. - Among patients with postoperative thoracic oligo-recurrence/metastasis of non-small-cell lung cancer (NLCLC), researchers assessed if stereotactic body radiotherapy (SBRT) using CyberKnife offers a safe and effective treatment strategy. The prognostic factors impacting overall survival post-SBRT were also investigated. A review was conducted with 44 participants with postoperative thoracic oligo-recurrence/metastatic of NLCLC managed with SBRT. A median overall survival (OS) of 52.60 months was seen, when measured from the date of salvage SBRT. The 1-,3-and 5-year OS rates and local control rates were estimated to be 97.7%, 65.3%, 47.7%, and 97.7%, 85.1% and 80.1%, respectively. The progression-free survival rates at 1, 3 and 5 years were 77.1%, 28.8% and 5.3%, respectively. Findings demonstrated encouraging efficacy of SBRT as a salvage treatment choice for postoperative thoracic oligo-recurrence/metastasis of non-small-cell lung cancer, as well as its acceptable toxicity profile. A better prognosis and longer survival were observed in relation to low pre-SBRT neutrophil-to-lymphocyte ratio and low Charlson comorbidity index. These may be regarded as dependable as well as independent prognostic factors in these patients managed with SBRT.